H.C. Wainwright initiated coverage on OmniAb with a new price target
$OABI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
H.C. Wainwright initiated coverage of OmniAb with a rating of Buy and set a new price target of $11.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2023 | $6.00 | Outperform | RBC Capital Mkts |
| 4/21/2023 | $8.00 | Buy | The Benchmark Company |
| 4/13/2023 | $10.00 | Buy | Craig Hallum |
| 2/22/2023 | $10.00 | Outperform | Cowen |
| 2/13/2023 | $11.00 | Buy | H.C. Wainwright |
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. "We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Third quarter results reflect consistent growth across key metrics, driven by our planned initiatives and the dedication of our team," said Matt Foehr, Chief Executive Officer of OmniAb. "Our business is well capitalized, and we have a highly scalable model with cutting-
OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating in two investor conferences during the month of November. Stifel 2024 Healthcare Conference, November 18-19 at the Lotte New York Palace Hotel. Kurt Gustafson, Chief Financial Officer, will participate in one-on-one meetings with investors on Tuesday, November 19th. Jefferies London Healthcare Conference, November 19-21 at the Waldorf Hilton. Matt Foehr, Chief Executive Officer, will participate in one-on-one and small-group meetings with investors on November 19-20. About OmniAb® OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discover
OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Tuesday, November 12, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss third quarter financial results and business updates Date: Tuesday, November 12, 2024 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (800) 549 8228 International (289) 819 1520 Conference ID is 943
SC 13G/A - OmniAb, Inc. (0001846253) (Subject)
SC 13D/A - OmniAb, Inc. (0001846253) (Subject)
RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00
The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00
Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00
10-Q - OmniAb, Inc. (0001846253) (Filer)
8-K - OmniAb, Inc. (0001846253) (Filer)
10-Q - OmniAb, Inc. (0001846253) (Filer)
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. "We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Third quarter results reflect consistent growth across key metrics, driven by our planned initiatives and the dedication of our team," said Matt Foehr, Chief Executive Officer of OmniAb. "Our business is well capitalized, and we have a highly scalable model with cutting-
OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Tuesday, November 12, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss third quarter financial results and business updates Date: Tuesday, November 12, 2024 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (800) 549 8228 International (289) 819 1520 Conference ID is 943
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates. "Second quarter results were in-line with our expectations and support our view of the full year. We advanced our business by adding new partnerships and programs as existing partners made important clinical progress in their respective programs," said Matt Foehr, Chief Executive Officer of OmniAb. "With recent momentum in business development, 2024 has the potential to be a record year in terms of deal flow, which we believe is driven by the quality and differe
Engineered chickens producing single domain antibodies (sdAbs) provided the scientific foundation for OmnidAb™, the Company's novel transgenic chicken platform launched in 2023 that generates fully human and stabilized sdAbs
Technical synergies between xPloration, OmniFlic®, OmniClic® and OmniDeep®enable new bispecific antibody discovery workflows for OmniAb's partnersOmniAb, Inc. (NASDAQ:OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today the Company presented an overview of xPloration, a high-throughput single B-cell screening platform that leverages machine learning and Artificial Intelligence (AI), in a presentation titled "Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibody Discovery."
Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $8 price target.
OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our